Rebecca Langhough Koscik

Rebecca Langhough Koscik

Auto-generated profile, based on publicly available information

Rebecca Langhough Koscik

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
SNScott C. Neu
Scott C. Neu
JPJudy Pa
Judy Pa
WKWalter Kukull
Walter Kukull
DBDuane Beekly
Duane Beekly
AKAmanda Kuzma
Amanda Kuzma
ATArthur W. Toga
Arthur W. Toga
For nearly 20 years, the prevalent view has been that women who carry copies of the ε4 allele of the apolipoprotein E (APOE) gene have a greater risk of developing Alzheimer disease (AD) than men with the same number of copies.1 The ε4 allele is the main genetic risk factor for late-onset Alzheimer disease (AD),2 and sex-based differences in AD risk have important implications for treatment trials, diagnostics, and therapeutics.3 Additionally, the sex-dependent relationship between APOE and mild cognitive impairment (MCI), which is often a transitional phase from cognitively normal (NL) aging to dementia,4 is unclear. Studies are in general agreement that the APOE ε4 allele is a risk factor for developing MCI,5-11 but there is controversy as to whether it increases10,12-14 or does not increase9,11,15,16 the risks of transitioning from MCI to AD or dementia. The 3 most common alleles of the APOE gene are ε2, ε3, and ε4; whereas carrying the ε4 allele increases one’s risk of developing AD, the ε2 allele conversely has a putative protective effect that is associated with longevity and a lower AD risk.17

1 December 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
NANicholas J. Ashton
Nicholas J. Ashton
SJShorena Janelidze
Shorena Janelidze
NMNiklas Mattsson-Carlgren
Niklas Mattsson-Carlgren
ABAlexa Pichet Binette
Alexa Pichet Binette
OSOlof Strandberg
Olof Strandberg
OHOskar Hansson
Oskar Hansson
Blood biomarkers indicative of Alzheimer’s disease (AD) pathology are altered in both preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the identification of AD pathology or monitoring of disease progression. Blood biomarkers that correlate with changes in cognition and atrophy during the course of the disease could be used in clinical trials to identify successful interventions and thereby accelerate the development of efficient therapies. When disease-modifying treatments become approved for use, efficient blood-based biomarkers might also inform on treatment implementation and management in clinical practice. In the BioFINDER-1 cohort, plasma phosphorylated (p)-tau231 and amyloid-β42/40 ratio were more changed at lower thresholds of amyloid pathology. Longitudinally, however, only p-tau217 demonstrated marked amyloid-dependent changes over 4–6 years in both preclinical and symptomatic stages of the disease, with no such changes observed in p-tau231, p-tau181, amyloid-β42/40, glial acidic fibrillary protein or neurofilament light. Only longitudinal increases of p-tau217 were also associated with clinical deterioration and brain atrophy in preclinical AD. The selective longitudinal increase of p-tau217 and its associations with cognitive decline and atrophy was confirmed in an independent cohort (Wisconsin Registry for Alzheimer’s Prevention). These findings support the differential association of plasma biomarkers with disease development and strongly highlight p-tau217 as a surrogate marker of disease progression in preclinical and prodromal AD, with impact for the development of new disease-modifying treatments.

1 September 2015 in Neurobiology of Aging
Verified
Journal Article
Closed access
KSKate E. Sprecher
Kate E. Sprecher
BBBarbara B. Bendlin
Barbara B. Bendlin
ARAnnie M. Racine
Annie M. Racine
OOOzioma C. Okonkwo
Ozioma C. Okonkwo
BCBradley Christian
Bradley Christian
RBRuth M. Benca
Ruth M. Benca

1 July 2011 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
SJSterling C. Johnson
Sterling C. Johnson
ARAsenath La Rue
Asenath La Rue
BHBruce P. Hermann
Bruce P. Hermann
GXGuofan Xu
Guofan Xu
RKRebecca L. Koscik
Rebecca L. Koscik
MSMark A. Sager
Mark A. Sager

20 February 2014 in Dementia and Geriatric Cognitive Disorders
Verified
Journal Article
Open access
PDF file
RKRebecca L. Koscik
Rebecca L. Koscik
ARAsenath La Rue
Asenath La Rue
EJErin M. Jonaitis
Erin M. Jonaitis
OOOzioma C. Okonkwo
Ozioma C. Okonkwo
SJSterling C. Johnson
Sterling C. Johnson
MSMark A. Sager
Mark A. Sager
Aim: It is difficult to reliably detect the earliest signs of Alzheimer's disease (AD)-associated cognitive impairment. Our aim was to compare 3 psychometric methods of identifying amnestic mild cognitive impairment (aMCI) in a middle-aged longitudinal cohort enriched for AD risk. Methods: Wisconsin Registry for Alzheimer's Prevention (WRAP) participants with 3 waves of cognitive assessment over approximately 6 years were coded as meeting each of 3 psychometric aMCI definitions: (a) ‘aMCI standard-baseline' used published norms to establish cutoffs for baseline performance; (b) ‘aMCI robust-baseline' applied WRAP-specific robust norms to baseline, and (c) ‘aMCI robust-multiwave' applied these robust norms across 3 waves of assessment. Each group was compared to a cognitively healthy subset. Results: Half the aMCI standard-baseline and one third of the aMCI robust-baseline group reverted to normal ranges at follow-up. Only the aMCI robust-multiwave method had an aMCI × age interaction showing significantly worse age-related memory declines in the aMCI group compared to the cognitively healthy group over 6 years of follow-up. Conclusion: Both cross-sectional methods showed instability over time, with many reverting to normal performance after baseline. The multiwave approach identified a group who showed progressive memory declines over 3 visits. Being able to detect progressive decline in late middle age is a critical step in improving prevention efforts.

26 July 2021 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
RKRebecca Langhough Koscik
Rebecca Langhough Koscik
BHBruce P. Hermann
Bruce P. Hermann
SASamantha Allison
Samantha Allison
LCLindsay R. Clark
Lindsay R. Clark
EJErin M. Jonaitis
Erin M. Jonaitis
SJSterling C. Johnson
Sterling C. Johnson
While clinically significant cognitive impairment is the key feature of the symptomatic stages of the Alzheimer’s disease (AD) continuum, subtle cognitive decline is now known to occur years before a clinical diagnosis of mild cognitive impairment (MCI) or dementia due to AD is made. The primary aim of this study was to examine criterion validity evidence for an operational definition of “cognitively unimpaired-declining” (CU-D) in the Wisconsin Registry for Alzheimer’s Prevention (WRAP), a longitudinal cohort study following cognition and risk factors from mid-life and on. Cognitive status was determined for each visit using a consensus review process that incorporated internal norms and published norms; a multi-disciplinary panel reviewed cases first to determine whether MCI or dementia was present, and subsequently whether CU-D was present, The CU-D group differed from CU-stable (CU-S) and MCI on concurrent measures of cognition, demonstrating concurrent validity. Participants who changed from CU-S to CU-D at the next study visit demonstrated greater declines than those who stayed CU-S. In addition, those who were CU-D were more likely to progress to MCI or dementia than those who were CU-S (predictive validity). In a subsample with positron emission tomography (PET) imaging, the CU-D group also differed from the CU-S and MCI/Dementia groups on measures of amyloid and tau burden, indicating that biomarker evidence of AD was elevated in those showing sub-clinical (CU-D) decline. Together, the results corroborate other studies showing that cognitive decline begins long before a dementia diagnosis and indicate that operational criteria can detect subclinical decline that may signal AD or other dementia risk.